ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Also Anna Barker gets new, longer title at NCI; Mark Clanton named deputy director for care, delivery.

February 13, 2004

Fallout Over PSA Guidance Continues—Specialty Groups Dissent, Congress Attacks

July 20, 2012

Advanced Screening Provides More Accurate Diagnosis

February 23, 2007

NCI-Frederick Leases Office Building To Move Some Programs Off Army Base.

February 26, 2010

Vanderbilt Recruits Sosman To Lead Tumor Immunology.

January 18, 2002

Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia

September 27, 2013